<?xml version='1.0' encoding='utf-8'?>
<document id="19997573"><sentence text="Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals."><entity charOffset="34-46" id="DDI-PubMed.19997573.s1.e0" text="pitavastatin" /></sentence><sentence text="Pitavastatin is a potent HMG-CoA reductase inhibitor and efficient hepatocyte low-density lipoprotein cholesterol (LDL-C) receptor inducer, producing robust reduction of the serum LDL-C levels, even at a low dose"><entity charOffset="0-12" id="DDI-PubMed.19997573.s2.e0" text="Pitavastatin" /><entity charOffset="102-113" id="DDI-PubMed.19997573.s2.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.19997573.s2.e0" e2="DDI-PubMed.19997573.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19997573.s2.e0" e2="DDI-PubMed.19997573.s2.e1" /></sentence><sentence text=" Pitavastatin and its lactone form are minimally metabolized by CYP enzymes, and are therefore associated with minimal drug-drug interactions (DDIs)"><entity charOffset="1-13" id="DDI-PubMed.19997573.s3.e0" text="Pitavastatin" /><entity charOffset="22-29" id="DDI-PubMed.19997573.s3.e1" text="lactone" /><pair ddi="false" e1="DDI-PubMed.19997573.s3.e0" e2="DDI-PubMed.19997573.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19997573.s3.e0" e2="DDI-PubMed.19997573.s3.e1" /></sentence><sentence text=" Pitavastatin 2 to 4 mg has potent LDL-C-reducing activity, equivalent to that of atorvastatin 10 to 20 mg; several clinical trials have revealed consistently superior high-density lipoprotein cholesterol (HDL-C) elevating activity of pitavastatin than that of atorvastatin"><entity charOffset="1-13" id="DDI-PubMed.19997573.s4.e0" text="Pitavastatin" /><entity charOffset="82-94" id="DDI-PubMed.19997573.s4.e1" text="atorvastatin" /><entity charOffset="193-204" id="DDI-PubMed.19997573.s4.e2" text="cholesterol" /><entity charOffset="206-211" id="DDI-PubMed.19997573.s4.e3" text="HDL-C" /><entity charOffset="235-247" id="DDI-PubMed.19997573.s4.e4" text="pitavastatin" /><entity charOffset="261-273" id="DDI-PubMed.19997573.s4.e5" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e0" e2="DDI-PubMed.19997573.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e0" e2="DDI-PubMed.19997573.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e0" e2="DDI-PubMed.19997573.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e0" e2="DDI-PubMed.19997573.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e0" e2="DDI-PubMed.19997573.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e0" e2="DDI-PubMed.19997573.s4.e5" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e1" e2="DDI-PubMed.19997573.s4.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e1" e2="DDI-PubMed.19997573.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e1" e2="DDI-PubMed.19997573.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e1" e2="DDI-PubMed.19997573.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e1" e2="DDI-PubMed.19997573.s4.e5" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e2" e2="DDI-PubMed.19997573.s4.e2" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e2" e2="DDI-PubMed.19997573.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e2" e2="DDI-PubMed.19997573.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e2" e2="DDI-PubMed.19997573.s4.e5" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e3" e2="DDI-PubMed.19997573.s4.e3" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e3" e2="DDI-PubMed.19997573.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e3" e2="DDI-PubMed.19997573.s4.e5" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e4" e2="DDI-PubMed.19997573.s4.e4" /><pair ddi="false" e1="DDI-PubMed.19997573.s4.e4" e2="DDI-PubMed.19997573.s4.e5" /></sentence><sentence text=" Pitavastatin-induced HDL-C elevation has been shown to be sustained, even incremental, in long-term clinical trials"><entity charOffset="1-13" id="DDI-PubMed.19997573.s5.e0" text="Pitavastatin" /><entity charOffset="22-27" id="DDI-PubMed.19997573.s5.e1" text="HDL-C" /><pair ddi="false" e1="DDI-PubMed.19997573.s5.e0" e2="DDI-PubMed.19997573.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19997573.s5.e0" e2="DDI-PubMed.19997573.s5.e1" /></sentence><sentence text=" Pitavastatin was as well-tolerated as atorvastatin or simvastatin in double-blind randomized clinical trials"><entity charOffset="1-13" id="DDI-PubMed.19997573.s6.e0" text="Pitavastatin" /><entity charOffset="39-51" id="DDI-PubMed.19997573.s6.e1" text="atorvastatin" /><entity charOffset="55-66" id="DDI-PubMed.19997573.s6.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.19997573.s6.e0" e2="DDI-PubMed.19997573.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19997573.s6.e0" e2="DDI-PubMed.19997573.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s6.e0" e2="DDI-PubMed.19997573.s6.e2" /><pair ddi="false" e1="DDI-PubMed.19997573.s6.e1" e2="DDI-PubMed.19997573.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s6.e1" e2="DDI-PubMed.19997573.s6.e2" /></sentence><sentence text=" Two-year long-term safety and effectiveness of pitavastain has been confirmed in a large-scale, prospective post-marketing surveillance"><entity charOffset="48-59" id="DDI-PubMed.19997573.s7.e0" text="pitavastain" /></sentence><sentence text=" The safety and efficacy profile of pitavastatin is favorable for the treatment of dyslipidemia, especially in metabolic syndrome patients"><entity charOffset="36-48" id="DDI-PubMed.19997573.s8.e0" text="pitavastatin" /></sentence><sentence text=" In addition to control of LDL-C, adequate control of triglyceride (TG) and HDL-C, hypertension and hyperglycemia is also necessary in metabolic syndrome patients"><entity charOffset="54-66" id="DDI-PubMed.19997573.s9.e0" text="triglyceride" /><entity charOffset="68-70" id="DDI-PubMed.19997573.s9.e1" text="TG" /><entity charOffset="76-81" id="DDI-PubMed.19997573.s9.e2" text="HDL-C" /><pair ddi="false" e1="DDI-PubMed.19997573.s9.e0" e2="DDI-PubMed.19997573.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19997573.s9.e0" e2="DDI-PubMed.19997573.s9.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s9.e0" e2="DDI-PubMed.19997573.s9.e2" /><pair ddi="false" e1="DDI-PubMed.19997573.s9.e1" e2="DDI-PubMed.19997573.s9.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s9.e1" e2="DDI-PubMed.19997573.s9.e2" /></sentence><sentence text=" Pitavastatin produces adequate control of LDL-C and TG, along with potent and incremental HDL-C elevation, with a low frequency of DDIs"><entity charOffset="1-13" id="DDI-PubMed.19997573.s10.e0" text="Pitavastatin" /><entity charOffset="53-55" id="DDI-PubMed.19997573.s10.e1" text="TG" /><entity charOffset="91-92" id="DDI-PubMed.19997573.s10.e2" text="HDL-C" /><pair ddi="false" e1="DDI-PubMed.19997573.s10.e0" e2="DDI-PubMed.19997573.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19997573.s10.e0" e2="DDI-PubMed.19997573.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s10.e0" e2="DDI-PubMed.19997573.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19997573.s10.e1" e2="DDI-PubMed.19997573.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19997573.s10.e1" e2="DDI-PubMed.19997573.s10.e2" /></sentence><sentence text="" /></document>